Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Assessment of hematological toxicity in patients with advanced neuroendocrine tumors and extensive/innumerable bone metastases undergoing lutetium-177 DOTATATE treatment.
Authors
Osama M Mosalem
Mayo Clinic Florida, Jacksonville, FL
Osama M Mosalem , Tucker Coston , Tanmayi Pai , Bassam Bassam Sonbol , Ephraim E. Parent , Jason R. Young , Geoffrey Johnson , Ayse T. Kendi , Thorvardur Ragnar Halfdanarson , Jason S. Starr
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Symptoms, Toxicities, and Whole-Person Care
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 592)
DOI
10.1200/JCO.2024.42.3_suppl.592
Abstract #
592
Poster Bd #
H3
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
LANTana trial protocol: An open label, single arm, phase Ib study to evaluate the effect of pre-treatment with ASTX727 (a demethylating agent) followed by lutetium Lu 177 dotatate in patients with progressive, metastatic neuroendocrine neoplasias (NENs).
First Author: Rohini Sharma
First Author: Dalvinder Mandair
Poster
2024 ASCO Annual Meeting
Bone metastases and skeletal related events in patients with gastrointestinal neuroendocrine tumors.
First Author: Paula Bruges
Poster
2024 ASCO Genitourinary Cancers Symposium
Total and anatomically contextualized quantitative 18F-DCFPyL PET at biochemical recurrence to predict subsequent biochemical progression-free survival in patients with prostate cancer.
First Author: Hong Song